Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
Global Age-Related Macular Degeneration (AMD) drug market size was valued at USD 7.91 billion in 2024. The market is projected to grow from USD 8.43 billion in 2025 to USD 12.07 billion by 2031, exhibiting a CAGR of 6.4% during the forecast period.
Age-related macular degeneration (AMD) is a progressive ophthalmic condition and a leading cause of vision loss in individuals over 50. The disease specifically damages the macula, the central part of the retina responsible for sharp, straight-ahead vision required for activities like reading and driving. The primary pharmacological treatments include anti-VEGF (Vascular Endothelial Growth Factor) therapies, which are injected into the eye to inhibit the growth of abnormal blood vessels and slow disease progression. Key drug types dominating the market are Lucentis (ranibizumab), Eylea (aflibercept), and the widely used off-label option, Avastin (bevacizumab).
The market is experiencing steady growth, driven by the aging global population and the consequent rise in the prevalence of AMD. This demographic shift is a significant underlying driver. Furthermore, the introduction of next-generation therapies with extended dosing intervals, such as Eylea HD, improves patient compliance and is contributing to market expansion. The market is highly concentrated, with the top three players Regeneron Pharmaceuticals, Bayer HealthCare, and Novartis collectively holding a dominant share of approximately 79%. While North America is the largest market, accounting for about 65% of global revenue due to high treatment adoption and pricing, Europe follows as a significant region with a 29% share.
Aging Global Population and Rising AMD Prevalence
The primary driver for the Age-related Macular Degeneration (AMD) drug market is the rapidly growing elderly population worldwide. As age is the most significant risk factor for AMD, the increasing number of individuals over the age of 65 is directly contributing to a higher prevalence of the disease. It is estimated that over 196 million people globally were affected by AMD in 2020, a figure projected to rise to 288 million by 2040.
Advancements in Anti-VEGF Therapeutics
Continuous innovation and the dominance of anti-VEGF (Vascular Endothelial Growth Factor) therapies form the cornerstone of market growth. The development of longer-acting formulations, such as brolucizumab and the emerging high-dose aflibercept, which reduce treatment burden by extending injection intervals, is a major driver for patient adherence and market expansion.
Growing adoption of combination therapies and sustained-release drug delivery systems, including port delivery systems, is creating a significant growth vector by improving patient quality of life and clinical outcomes.
Increased healthcare expenditure, improved diagnostic capabilities with advanced imaging, and greater awareness of AMD and its treatment options are also fueling market growth, particularly in developed economies.
MARKET CHALLENGES
High Cost of Therapy and Treatment Burden
The high cost of anti-VEGF drugs and the requirement for frequent intravitreal injections present significant challenges. The recurring expenses for patients and healthcare systems, combined with the logistical burden of monthly or bimonthly clinic visits, can lead to suboptimal treatment adherence and outcomes, especially in resource-constrained settings.
Other Challenges
Limited Efficacy in Geographic Atrophy
While anti-VEGF drugs are effective for wet AMD, there remains a significant unmet need for approved pharmacological treatments for geographic atrophy (GA), the advanced form of dry AMD. The recent approval of the first two GA treatments (pegcetacoplan and avacincaptad pegol) is nascent, and challenges related to their efficacy, safety, and cost-effectiveness persist.
Stringent Regulatory Hurdles and Safety Concerns
The development of novel AMD therapies faces rigorous regulatory pathways due to the sensitive nature of intraocular treatments. Safety concerns, such as intraocular inflammation associated with some newer anti-VEGF agents, require extensive clinical trials and post-market surveillance, potentially delaying market entry.
Patent Expirations and Biosimilar Competition
The impending patent expirations for key branded anti-VEGF drugs, notably ranibizumab, are a major market restraint. The subsequent entry of biosimilars is expected to create significant pricing pressure, eroding the revenue of originator products and constraining overall market value growth despite potentially increasing treatment access.
Unfavorable Reimbursement Scenarios
Reimbursement policies and pricing pressures from payers and government health agencies in various countries can limit the adoption of high-cost innovative therapies. Restrictive formularies and complex reimbursement processes can act as barriers to patient access for newer, more expensive treatment options.
Emerging Markets and Untapped Patient Pools
Significant growth opportunities exist in emerging economies across Asia-Pacific and Latin America, where improving healthcare infrastructure, rising disposable incomes, and growing awareness of retinal diseases are expanding the addressable patient population for AMD therapeutics.
Pipeline of Novel Therapeutic Modalities
The robust pipeline featuring gene therapies, sustained-release implants, and oral medications presents substantial opportunities. These next-generation therapies aim to provide one-time or less frequent treatments, potentially revolutionizing disease management and capturing significant market share by addressing the critical unmet need for reduced treatment frequency.
Expansion into Early-Stage and Dry AMD Treatment
The development of effective treatments for early and intermediate dry AMD represents a massive, largely untapped market opportunity. Success in this area would drastically expand the patient base beyond the current focus on the smaller wet AMD segment, offering a major growth avenue for pharmaceutical companies.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Eylea is widely considered the current market leader due to its strong clinical efficacy profile and established physician preference for treating both wet and diabetic macular edema forms of AMD. Lucentis remains a formidable competitor with a proven track record, while Avastin serves as a critical cost-effective alternative, particularly in budget-conscious healthcare systems, despite being used off-label. The 'Others' category includes newer anti-VEGF agents and emerging therapies that are gaining traction and represent the future innovation pipeline for addressing unmet medical needs in this chronic condition. |
| By Application |
|
Hospitals represent the dominant channel for AMD drug administration, driven by the requirement for specialized injection procedures by retinal specialists and the complex nature of patient management. Major tertiary care hospitals with dedicated ophthalmology departments are the primary sites for treatment initiation and complex case management. However, specialized ophthalmology clinics are increasingly important for routine follow-up injections and monitoring, offering greater convenience for patients requiring long-term, frequent treatments. The 'Others' segment includes ambulatory surgery centers, which are growing in prominence due to efficiency and cost-containment pressures within healthcare systems. |
| By End User |
|
Geriatric Population is the unequivocal core end-user segment for AMD drugs, as age is the primary risk factor for the disease. This demographic's growing global prevalence directly fuels market demand, creating a consistent and expanding patient pool. The management of comorbidities and polypharmacy in this group presents unique challenges for treatment regimens. The adult population with early-onset AMD, while smaller, represents a significant segment due to the profound impact of vision loss on working-age individuals and the potential for longer-term treatment durations. The 'Others' category may include patients with specific genetic predispositions or rare subtypes of the disease. |
| By Disease Stage |
|
Wet AMD is the leading segment in terms of current pharmaceutical intervention, as it is characterized by rapid vision loss requiring immediate and continuous anti-VEGF therapy to prevent blindness. This segment drives the majority of the branded drug market revenue due to the high cost and frequent dosing of these biologic treatments. In contrast, the dry AMD segment, which is more common but progresses slowly, currently has limited treatment options, creating a significant unmet need and a major area for future drug development and commercial opportunity as therapeutic breakthroughs emerge. |
| By Route of Administration |
|
Intravitreal Injection is the unequivocal standard and leading route of administration for approved AMD therapeutics, delivering drugs directly to the site of action in the eye. This method ensures high local bioavailability but imposes a significant treatment burden on patients due to the need for frequent clinic visits. The search for less invasive alternatives is a key market driver, with oral medications representing a major area of research focus due to their potential for improved patient compliance and convenience. Emerging routes, such as sustained-release implants, aim to reduce injection frequency and are viewed as the next frontier in treatment innovation, promising to reshape the competitive landscape. |
A Consolidated Market Dominated by Anti-VEGF Innovators
The global Age-Related Macular Degeneration (AMD) drug market is characterized by a high degree of consolidation, with the top 3 players commanding approximately 79% of the market share. This dominance is largely driven by the entrenched positions of biologic drugs targeting vascular endothelial growth factor (VEGF). Regeneron Pharmaceuticals, in partnership with Bayer HealthCare, leads the market with its blockbuster drug Eylea (aflibercept). Following closely is Novartis, the marketer of Lucentis (ranibizumab), a long-standing standard of care. Roche, which originally developed Lucentis, also holds significant market influence and distributes the widely used off-label treatment, Avastin (bevacizumab). The competitive dynamics are heavily influenced by product efficacy, dosing frequency, pricing strategies, and intellectual property landscapes.
Beyond the market leaders, a cohort of other significant players compete through niche strategies, including biosimilars, novel mechanisms of action, and geographic focus. Companies like Kanghong Pharma are prominent players, particularly in the Asian markets. The competitive landscape is further populated by emerging biopharmaceutical companies advancing next-generation therapies, such as longer-acting anti-VEGF agents, sustained-release formulations, and treatments targeting alternative pathways like the complement system. These players aim to capture market share by addressing unmet needs related to treatment burden and efficacy in specific AMD patient populations. The market also includes suppliers of the widely used, cost-effective anti-VEGF agent, bevacizumab, which is often compounded for ophthalmic use.
List of Key Age Related Macular Degeneration Drug Companies ProfiledRegeneron Pharmaceuticals
Novartis AG
Kanghong Pharmaceutical Group
Pfizer Inc.
Alimera Sciences, Inc.
EyePoint Pharmaceuticals, Inc.
Graybug Vision, Inc.
Kodiak Sciences Inc.
Opthea Limited
Iveric Bio (an Astellas Company)
Apellis Pharmaceuticals, Inc.
The global Age Related Macular Degeneration Drug market is on a definitive growth trajectory, projected to increase from a valuation of $7,905 million in 2024 to $12,070 million by 2031, representing a compound annual growth rate (CAGR) of 6.4%. This sustained expansion is primarily fueled by the growing aging population globally, which is leading to a higher prevalence of AMD, a disease that blurs central vision by affecting the macula. The demand for effective treatments to manage this chronic condition is a central driver of market growth, creating a stable and expanding revenue base for key therapies.
Other TrendsDominance of Anti-VEGF Therapies
The market is overwhelmingly dominated by anti-VEGF (Vascular Endothelial Growth Factor) drugs, which are the standard of care for the more common wet form of AMD. Key products in this segment include Lucentis (ranibizumab), Eylea (aflibercept), and the widely used off-label option, Avastin (bevacizumab). These intravitreal injections work by inhibiting abnormal blood vessel growth and leakage in the eye, effectively slowing disease progression and preserving vision. The competitive dynamics and market share of these specific drugs are a critical trend shaping manufacturer strategies.
Regional Market Concentration
A significant trend is the high concentration of the market in developed regions. North America is the largest market, holding approximately 65% of the global share, largely due to high treatment adoption rates, advanced healthcare infrastructure, and favorable reimbursement policies. Europe follows as the second-largest market, accounting for about 29% of the global share. This geographical concentration underscores the importance of regulatory and pricing strategies in these key regions for market participants.
Consolidated Competitive LandscapeThe competitive environment is characterized by a high degree of consolidation among a few major pharmaceutical companies. The top three players Regeneron Pharmaceuticals, Bayer HealthCare, and Novartis collectively occupy approximately 79% of the market share. This concentration creates a high-barrier-to-entry market where innovation, strategic partnerships, and life-cycle management of blockbuster drugs like Eylea are paramount for maintaining leadership. The market dynamics are heavily influenced by the research, development, and marketing activities of these dominant entities.
Regional Analysis: Age Related Macular Degeneration Drug MarketEurope
Europe represents a significant and advanced market for AMD drugs, characterized by strong, universally accessible healthcare systems that provide broad coverage for approved treatments. Countries like Germany, the UK, and France are key contributors, with well-established protocols for managing retinal diseases. The European Medicines Agency (EMA) provides a centralized approval pathway, though pricing and reimbursement negotiations can vary by country, impacting the speed of market access for new drugs. There is a strong emphasis on cost-effectiveness and health technology assessments, which can influence prescribing patterns. The aging demographic profile across the continent ensures a steadily growing patient base. Research collaboration is strong within the EU, contributing to the region's role in global clinical development for new AMD therapies, including those for geographic atrophy.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for AMD drugs, driven by a rapidly aging population, increasing healthcare expenditure, and improving diagnostic capabilities. Japan stands out as a mature market with a high burden of disease and a sophisticated healthcare system, while countries like China and India present immense growth potential due to their vast populations. Market access is expanding as awareness of AMD rises and healthcare infrastructure improves, particularly in urban centers. However, challenges remain, including disparities in healthcare access between urban and rural areas and varying reimbursement policies. Local pharmaceutical companies are becoming increasingly active in developing biosimilars and novel therapies, aiming to capture a share of this expanding market.
South America
The AMD drug market in South America is emerging, with growth potential tied to economic development and healthcare modernization. Brazil and Argentina are the largest markets, but access to advanced therapies can be limited by economic volatility and constrained public health budgets. Treatment penetration is often higher in major cities where specialized retinal care is available. While awareness is growing, diagnosis and treatment rates are generally lower than in more developed regions. The market is characterized by a reliance on older, more affordable treatments in some areas, though there is a gradual uptake of newer anti-VEGF drugs among patients who can afford them or are covered by private insurance.
Middle East & Africa
This region exhibits a highly heterogeneous market for AMD drugs. The Gulf Cooperation Council (GCC) countries, such as Saudi Arabia and the UAE, have well-funded healthcare systems that provide access to advanced treatments, resembling markets in developed nations. In contrast, many parts of Africa face significant challenges, including limited healthcare infrastructure, a lack of specialists, and low awareness of AMD, leading to substantial under-diagnosis and treatment. The market is largely concentrated in urban private healthcare settings. International aid and initiatives are slowly helping to build capacity, but overall market size remains small relative to the potential patient population due to these systemic barriers.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global Age-Related Macular Degeneration Drug market was valued at USD 7.91 billion in 2024 and is expected to reach USD 12.07 billion by 2031.
Which key companies operate in Global Age-Related Macular Degeneration Drug Market?
-> Key players include Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, and Kanghong Pharma, among others.
-> Key growth drivers include aging global population, rising prevalence of AMD, and development of extended-dosing therapies.
-> North America is the largest market, accounting for about 65% of global revenue.
-> Emerging trends include next-generation anti-VEGF therapies, personalized treatment approaches, and increasing focus on combination therapies.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates